IDXX - IDEXX Laboratories Inc
221
$579.85
$2.73 (0.473%)
$579.86
$0.01 (0.002%)
Score4.06/5
Price Targets
49.0%
32.5%
-17.2%
Most Recent Recommendations
Revenue Estimate
- Past Revenue
- Avg
- High
- Low
EPS Estimate
- Past EPS
- Avg
- High
- Low
Revenue Estimate as % change
| 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | |
|---|---|---|---|---|---|---|---|---|
| Low | 8.39% | 7.88% | 8.04% | 7.46% | 11.5% | 17.7% | 8.41% | 7.98% |
| Avg | 9.13% | 8.60% | 9.23% | 8.89% | 11.5% | 13.1% | 8.42% | 7.98% |
| High | 9.60% | 9.94% | 11.1% | 11.0% | 9.74% | 8.86% | 8.41% | 7.98% |
EPS Estimate as % change
| 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | |
|---|---|---|---|---|---|---|---|---|
| Low | 14.9% | 9.08% | 9.28% | 9.20% | 21.2% | 30.9% | 12.0% | 11.2% |
| Avg | 12.7% | 12.7% | 13.4% | 10.6% | 18.7% | 21.1% | 12.0% | 11.2% |
| High | 13.4% | 14.7% | 16.8% | 16.3% | 14.2% | 12.8% | 12.0% | 11.2% |
Recommendation Trends
- Strong Sells
- Sells
- Holds
- Buys
- Strong Buys
Latest Analyst Ratings
Institution | Action | Grade | Old Grade | Date |
|---|---|---|---|---|
| Piper Sandler | Maintain | Neutral | Neutral | 2026-02-09 |
| Barclays | Maintain | Overweight | Overweight | 2026-02-05 |
| UBS | Maintain | Neutral | Neutral | 2026-02-03 |
| BTIG | Maintain | Buy | Buy | 2026-02-03 |
| Barclays | Init | Overweight | -- | 2025-12-09 |
| JP Morgan | Maintain | Overweight | Overweight | 2025-11-04 |
| UBS | Maintain | Neutral | Neutral | 2025-11-04 |
| Morgan Stanley | Maintain | Overweight | Overweight | 2025-11-04 |
| BTIG | Maintain | Buy | Buy | 2025-11-04 |
| Stifel | Upgrade | Buy | Hold | 2025-10-31 |